TSRL

read moreTherapeutic Systems Research Laboratories (TSRL), Inc. is a privately owned preclinical accelerator based in Ann Arbor, Michigan. Our 7,200 sq. We build on our success co-developing technologies through academic partnerships by providing infrastructure, expertise, and an avenue to non-dilutive funding. In an effort to advance our lead candidates into clinical development, we have developed an asset-centric portfolio built on promising lead-stage anti-infective compounds. TSRL, Inc., a preclinical accelerator, announces the appointments of Martha Farmer, PhD, and Stephen Munk, PhD to the Board of Directors, and Gregory Amidon, PhD, current board member, as Chairman.

read moreWe are a team of passionate pharmaceutical scientists and business development professionals who leverage our talent, infrastructure, and network to remove the barriers for preclinical development, translating promising drug therapy concepts into IND-enabling product opportunities. Based in Ann Arbor, Michigan, TSRL's Technology Accelerator creates value by providing a combination of business and scientific expertise, infrastructure, and wet-lab data to take drug-therapy concepts to business formation or licensing-readiness.

read moreOur team has broad experience in chemistry, molecular biology, biochemistry, analytical chemistry, in vivo animal model, PK/ADME, toxicology and formulation R&D. We also employ senior consultants and business development professionals on a project-by-project basis with experience from all stages of drug development. Dr. Elke Lipka joined TSRL in June of 2007 to develop and implement a sustainable competitive commercialization strategy for TSRL's technology portfolio. She was promoted to CEO in November 2018.

read moreTSRL is a private, preclinical accelerator based in Ann Arbor, Michigan, focused on translating early-stage infectious disease therapeutics into viable clinical assets. We are a team of pharma industry veterans with deep drug development expertise, ranging from discovery and preclinical development to clinical, regulatory, and IP strategy development. We enhance research collaborations by championing grant applications, licensing agreements, and mergers and acquisitions. We have developed a technology portfolio primarily focused on analogs of antimicrobial drug candidates.